Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Primary relevance to vitamin D Vitamin D is a stated subject of this paper.

Vitamin D is a stated subject of this paper; the supporting source evidence is shown below.

Why this paper is included

Supporting source evidence:

Vitamin D is used to reduce cancer risk and improve the outcome of cancer patients, but the vitamin D receptor (VDR; also known as the calcitriol receptor) pathway needs to be functionally intact to ensure the biological effects of circulating calcitriol, the active form of vitamin D.

Source: Abstract. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Laboratory / cell research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

We observed that ERRα functionally supported the proliferation of BC cell lines and acted as a calcitriol‐induced regulator of VDR.

Source: Abstract.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

The ERRα-VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR‐CYP24A1‐ERRα overexpression correlates with poor prognosis in patients with basal‐like breast cancer

Study design awaiting verification · Molecular Oncology · 2021

Original publication title

The ERRα: VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR‐CYP24A1‐ERRα overexpression correlates with poor prognosis in patients with basal‐like breast cancer

Katia Danza; Letizia Porcelli; Simona De Summa; Roberta Di Fonte; Brunella Pilato; Rosanna Lacalamita; Simona Serratì; Amalia Azzariti; Stefania Tommasi

© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

At a glance

What does the authors’ abstract report?

Vitamin D is used to reduce cancer risk and improve the outcome of cancer patients, but the vitamin D receptor (VDR; also known as the calcitriol receptor) pathway needs to be functionally intact to ensure the biological effects of circulating calcitriol, the active form of vitamin D. Besides estrogen receptor alpha (ERα), estrogen‐related receptor alpha (ERRα) has also been shown to interfere with the VDR pathway, but its role in the antitumor and transactivation activity of calcitriol is completely unknown in breast cancer (BC).

We observed that ERRα functionally supported the proliferation of BC cell lines and acted as a calcitriol‐induced regulator of VDR. As such, ERRα deregulated the calcitriol: VDR transcription by enhancing the expression of CYP24A1 as well as of both ERα and aromatase (CYP19A1) in calcitriol‐treated cells. ERRα knockdown limited the effect of calcitriol by reducing calcitriol‐induced G0/G1 phase cell cycle arrest and by affecting the expression of cyclin D1 and p21/Waf. The interactome analysis suggested that Peroxisome Proliferator‐Activated Receptor Gamma Coactivator 1‐α (PGC‐1α) and Proline‐, glutamic acid‐, and leucine‐rich protein 1 (PELP1) are key players in the genomic actions of the calcitriol: VDR: ERRα axis.

Evaluation of patient outcomes in The Cancer Genome Atlas (TCGA) dataset showed the translational significance of the biological effects of the VDR: ERRα axis, highlighting that VDR, CYP24A1, and ERRα overexpression correlates with poor prognosis in basal‐like BC.

Authors’ abstract

Vitamin D is used to reduce cancer risk and improve the outcome of cancer patients, but the vitamin D receptor (VDR; also known as the calcitriol receptor) pathway needs to be functionally intact to ensure the biological effects of circulating calcitriol, the active form of vitamin D. Besides estrogen receptor alpha (ERα), estrogen‐related receptor alpha (ERRα) has also been shown to interfere with the VDR pathway, but its role in the antitumor and transactivation activity of calcitriol is completely unknown in breast cancer (BC).

We observed that ERRα functionally supported the proliferation of BC cell lines and acted as a calcitriol‐induced regulator of VDR. As such, ERRα deregulated the calcitriol: VDR transcription by enhancing the expression of CYP24A1 as well as of both ERα and aromatase (CYP19A1) in calcitriol‐treated cells. ERRα knockdown limited the effect of calcitriol by reducing calcitriol‐induced G0/G1 phase cell cycle arrest and by affecting the expression of cyclin D1 and p21/Waf. The interactome analysis suggested that Peroxisome Proliferator‐Activated Receptor Gamma Coactivator 1‐α (PGC‐1α) and Proline‐, glutamic acid‐, and leucine‐rich protein 1 (PELP1) are key players in the genomic actions of the calcitriol: VDR: ERRα axis.

Evaluation of patient outcomes in The Cancer Genome Atlas (TCGA) dataset showed the translational significance of the biological effects of the VDR: ERRα axis, highlighting that VDR, CYP24A1, and ERRα overexpression correlates with poor prognosis in basal‐like BC.

Publication and source details

Original title: The ERRα: VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR‐CYP24A1‐ERRα overexpression correlates with poor prognosis in patients with basal‐like breast cancer

Katia Danza; Letizia Porcelli; Simona De Summa; Roberta Di Fonte; Brunella Pilato; Rosanna Lacalamita; Simona Serratì; Amalia Azzariti; Stefania Tommasi

Molecular Oncology · 2021

* Correspondence
K. Danza, Molecular Diagnostics and Pharmacogenetics Unit, IRCCS Istituto Tumori Giovanni Paolo II, Viale Orazio Flacco, 65‐70124, Bari, Italy
E‐mail: danzakatia@gmail.com
and
L. Porcelli, Laboratory of Experimental Pharmacology, IRCCS Istituto Tumori Giovanni Paolo II, Viale Orazio Flacco, 65‐70124, Bari, Italy
E‐mail: porcelli.letizia@gmail.com
© 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.Italian Puglia Region funds Project: Tecnopolo per la Medicina di PrecisioneCUP B84I18000540002

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-11T12:35:50.924010+00:00

DOI: 10.1002/1878-0261.13013 · PMC8847991